Mirum Pharmaceuticals has raised $75m in its initial public offering that had an initial target of $86.3m and provided exits to Novo and Shire.

Mirum Pharmaceuticals, a US-based liver disease therapy developer backed by pharmaceutical firms Shire and Novo, issued 5 million shares priced at $15 on Wednesday to raise $75m in its initial public offering. The company began trading on the Nasdaq Global Market yesterday and saw its shares drop as low as $12.72 before recovering slightly to…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.